Particella
Oral mRNA Medicines
San Francisco, United States · Founded 2016
- Headquarters
- San Francisco, California
- Employees
- 1–10
- Founded
- 2016
- Business Model
- B2B
- Website
- particella.bio
- Last Round
- Convertible NoteMar 2023
- Rounds
- 2
About
Particella (formerly DNAlite Therapeutics) is a preclinical biotechnology company developing oral lipid nanoparticle technology to deliver nucleic acids to the intestinal epithelium. Its platform enables oral mRNA medicines with repeatable dosing that are non-immunogenic and patient-friendly, targeting a major unmet need in gene therapy drug delivery.
Summary
Particella is a Biotech company based in San Francisco, United States, founded in 2016. Its most recent funding was a Convertible Note round in Mar 2023. Investors include SOSV and IndieBio.
Funding History
Mar 2023
Sign up to see all 2 rounds
Series A through Convertible Note — per-round amounts, valuations, and who invested in each round.
Investors
Similar Companies
China's leading blood products manufacturer
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Simtra provides pharmaceutical and biotech clients development and manufacturing services for ste...
IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...
Altos Labs combines academic science and industry development to create medicines that restore ce...
inVentiv Health merged with INC Research to form Syneos Health, integrating clinical and commerci...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/particella"><img src="https://indexed.vc/api/badge/company/particella" alt="Particella on Indexed.vc" width="260" height="76" /></a>